trial data) that involve risk and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements.
The forward-looking statements are also identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential," "possible,"
"should," "continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in forward-looking
statements as a result of several factors, including regulatory approval
requirements and competitive conditions. These and other factors that may
result in differences are discussed in greater detail in the company's
reports on Forms 10-K, 10-Q, and other filings with the Securities and
Halozyme Contact Media Contact
David A. Ramsay Karen Sparks / Joleen Schultz
Chief Financial Officer Mentus
(858) 704-8260 (858) 455-5500, x275/x215
HALOZYME THERAPEUTICS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - UNAUDITED
FOR THE THREE MONTHS ENDED MARCH 31, 2008 AND 2007
Three Months Ended
Product sales $141,438 $187,086
Revenue under collaborative agreements 1,664,080 623,129
Total Revenues 1,805,518 810,215
Cost of product
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 92
. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results3
. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences4
. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 145
. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference6
. Halozyme Therapeutics Amends Stockholder Rights Plan7
. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results8
. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference9
. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology10
. Innovative and Forward-Thinking Experts to Deliver Keynote Presentations at IBCs 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress11
. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase